Clinical and parasitological efficacy of artesunate and sulfadoxine-pyrimethamine (AS+SP) for the treatment of uncomplicated falciparum malaria in different transmission settings in India
Journal of Vector Borne Diseases · 2025
DOI: 10.4103/jvbd.jvbd_212_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Vector Borne Diseases, 2025. Verfasst von Ritesh Ranjha und 8 weiteren Autor:innen. Beteiligte Einrichtung: ICMR-National Institute of Malaria Research, New Delhi, India. Hauptthemen laut MEDLINE: Sulfadoxine, Pyrimethamine, Malaria, Falciparum, Antimalarials. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background & objectives: In 2010, artesunate and sulfadoxine-pyrimethamine (AS+SP) were adopted as the first-line artemisinin based combination therapy for treatment of uncomplicated Plasmodium falciparum malaria in India. Continuous therapeutic efficacy monitoring of first line anti-malarial drugs is required to update the treatment policy for malaria control and elimination. This study aimed to assess the therapeutic efficacy of artesunate and sulfadoxine-pyrimethamine (AS+SP) at three sites with different diseases transmission intensity.
Methods
A 28-day, single-arm, prospective study was conducted to evaluate the clinical and parasitological response to AS+SP. Patients received a six-dose regimen of AS+SP over three days and were monitored for 28 days through clinical and laboratory assessments. Participant recruitment and outcome classification was done as per WHO guidelines for surveillance of anti-malarial drug efficacy.
Results
A total of 170 participants were enrolled and 147 of them completed the follow-up. Adequate clinical and parasitological response (ACPR) was observed in 100% of the study participants who completed the follow-up. 100% fever clearance as well as parasite clearance was observed on day 3. Interpretation & conclusion: This study demonstrated high therapeutic efficacy and a good safety profile for artesunate and sulfadoxine-pyrimethamine at different transmission intensities. This suggests the continuation of the current artemisinin-based combination therapy for the treatment of P. falciparum malaria in India.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICMR-National Institute of Malaria Research, New Delhi, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.
Zitieren
APA
Ranjha, R., Baharia, R., Vani, H. C., Srivastava, B., Ahmed, N., Sharma, S., Mallick, P. K., Anvikar, A. R., & Bharti, P. K. (2025). Clinical and parasitological efficacy of artesunate and sulfadoxine-pyrimethamine (AS+SP) for the treatment of uncomplicated falciparum malaria in different transmission settings in India. Journal of Vector Borne Diseases. https://doi.org/10.4103/jvbd.jvbd_212_24
Vancouver
Ranjha R, Baharia R, Vani HC, Srivastava B, Ahmed N, Sharma S, et al. Clinical and parasitological efficacy of artesunate and sulfadoxine-pyrimethamine (AS+SP) for the treatment of uncomplicated falciparum malaria in different transmission settings in India. Journal of Vector Borne Diseases. 2025. doi:10.4103/jvbd.jvbd_212_24
BibTeX
@article{Ranjha2025,
author = {Ranjha, Ritesh and Baharia, Rajendra and Vani, H Chalageri and Srivastava, Bina and Ahmed, Naseem and Sharma, Supriya and Mallick, Prashant Kumar and Anvikar, Anupkumar R and Bharti, Praveen Kumar},
title = {Clinical and parasitological efficacy of artesunate and sulfadoxine-pyrimethamine (AS+SP) for the treatment of uncomplicated falciparum malaria in different transmission settings in India},
journal = {Journal of Vector Borne Diseases},
year = {2025},
doi = {10.4103/jvbd.jvbd_212_24}
}
EUVIMED